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Mexicans and Mexican Americans share culture, genetic background, and predisposition
for chronic complications associated with obesity and diabetes making imperative
efficacious treatments and prevention. Obesity has been treated for centuries focused-on
weight loss while other treatments on associated conditions like gout, diabetes (T2D), and
hypertriglyceridemia. To date, there is no systematic review that synthesizes the origin of
obesity clinics in Mexico and the efforts to investigate treatments for obesity tested by
randomized clinical trials (RCT). We conducted systematic searches in Pubmed, Scopus,
and Web of Science to retrieve anti-obesity RCT through 2019 and without an inferior
temporal limit. The systematic review included RCT of anti-obesity treatments in the
Mexican adult population, covering alternative medicine, pharmacological, nutritional,
behavioral, and surgical interventions reporting metabolism-associated traits such as
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BMI, weight, waist circumference, triglycerides, glucose, among others. Only the
studies with at least 3 months of treatment were included in the meta-analyses in
order to reduce placebo effects. We found 634 entries, after removal of duplicates
and screening the studies based on eligibility criteria, we analyzed 43 national, and
2 multinational-collaborative studies. Most of the national studies had small sample
sizes, and the implemented strategies do not have replications in the population.
The nutrition/behavioral interventions were difficult to blind, and most studies have
medium-to-high risk of bias. Nutritional/behavioral interventions and medications showed
effects on BMI, waist circumference, and blood pressure. Simple measures like pure
water instead of sweet beverages decrease triglycerides and systolic blood pressure.
Dark chocolate showed the highest effect for BMI and high blood pressure, and treatment
with insulin increased weight in those with T2D. The study of obesity in Mexico has
been on-going for more than four decades, the interest on RCT just increased until
this millennium, but with small sample sizes and lack of replication. The interventions
affect different cardiometabolic associated traits, which should be analyzed in detail in
the population living near the Mexico-U.S. border; therefore, bi-national collaboration is
desirable to disentangle the cultural effects on this population’s treatment response.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_reco
rd.php?ID=CRD42020221436, identifier: CRD42020221436.
Keywords: anti-obesity agents, abdominal obesity metabolic syndrome, systematic review and meta-analysis,
randomized clinical trials, type 2 diabetes

INTRODUCTION

Since 1993 a series of population surveys have been conducted
systematically in Mexico using the BMI. The first National
Survey on Chronic Diseases (ENEC from Spanish: Encuesta
Nacional de Enfermedades Crónicas) highlighted obesity as a
national public health problem. The prevalence of obesity in
Mexico has increased substantially since the 1980s, and currently
affects over 30% of the adult population (3). The epidemiological
transition from undernourishment and infectious diseases to
emergent chronic diseases were well-documented in the ENEC.
A sequel of undernourishment in presence of an obesogenic
environment is homeorrhexis as an adaptive response to
undernourishment. Homeorrexis or homeorhesis comes from
the Greek homós, “equal;” and rhéxis, “violent rupture,” and
refers to regulatory mechanisms that allow the body to change
from one homeostatic, stable condition to another in a
programmed fashion, e.g., growth during childhood or the onset
of lactation (4). A combination of genetic and socioeconomic
strata were conditions affecting stature. From North to South
Mexico the ENEC data show a decrease in stature by expenses
of the lower body segment (Figure 1), the sitting height is almost
similar across regions. The stature can modify body composition
despite BMI (5) and can be an indicator of socioeconomic
inequality (6).
The First Obesity meeting in Mexico with the NAASO
and the Pan-American Endocrine Meetings were held in
Cancun in 1997. These meetings were a landmark achievement
for the study of obesity in Mexico with the first NOM
(Mexican Official Norm) for obesity management, published

Obesity in Mexico: A Story Never Told
The history of obesity as a clinical entity started with the
Obesity Clinic established in 1959 at the Instituto Nacional
de Nutrición Salvador Zubirán, by Dr. Luis Domenge, Dr.
Carmen Ramos, and Dr. Jorge Gonzalez-Barranco. They, as
expert physicians, considered obesity as an aesthetic but also a
medical problem. The so-called epidemiologic transition, from
infectious to chronic degenerative diseases, moved slowly from
the 70s and 80s derived from an evolution of treating obesity as
a medical problem, promoted by Dr. Gonzalez-Barranco based
on scientific research and clinical trials with medications in
the 90s.
The first attempt to classify obesity was using the Metropolitan
Life Insurance Company (MLIC) which developed standard
tables for “ideal” (MLIC 1942) and then “desirable” weight (MLIC
1959) based on the observed association of body weight with
mortality. These standard tables were the platform for developing
the current definition for underweight, normal, overweight, and
obese individuals based on the body mass index (BMI) cutoffs (1).
The use of BMI as a reliable measurement started with the
NHANES from 1988 to 2016. These studies demonstrated the
age-adjusted prevalence of obesity in the United States increased
progressively: from 22.9 to 39.6 percent. The main issue of
concern in regard to BMI involves the growing obesity epidemic
and the increasing population with high BMI numbers (2).
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FIGURE 1 | Height measurement standing up, sitting, and the lower body segment. From North to South, height is lower at the expenses of the lower body segment
(p < 0.0001, adjusted by Bonferroni for all regions). Sitting height reflects the upper body segment and shows small differences between regions. Means and standard
deviations. Data obtained from the ENEC 1993. CDMX, Mexico City; Sitting, sitting height; Lower, Lower segment of the body (Height-sitting height).

scores in Healthy Eating Index (HEI) indicating a better diet
quality. For vegetables, fruits, and proteins, middle-aged adults
had higher scores compared to young adults. Concerning HEI
components, a 1-unit increase of acculturation was associated
with 10 to 20% lower odds of attaining better scores for
vegetables, fruits, dairy, sodium, and empty calories in almost
all ages.

in 1998 (7). Since this new millennium, there has been
a spread of interest in obesity in other hospitals and
Mexican states. Close collaboration with the Diabetes Division
at the University of Texas San Antonio Health Science
Center (UTSAHSC) and the South Texas Diabetes and
Obesity Institute (STDOI) at the UTRGV has been done
since then.
In the United States, Mexican Americans are considered part
of the Hispanic Americans or Latino group. The U.S.-Mexico
border represents this minority with active immigration, and a
rapid increase in population. One of the Healthy People 2020
goals was to improve the health of all groups, requiring an
understanding of the Hispanic culture, and health care needs for
health promotion (8).

Medication Research and Current
Anti-obesity Guidelines
Some pharmacokinetics determinants of many drugs depend
on the body size; for instance, obesity modifies the volume
of distribution, and drug clearance, probably due to increased
activity of cytochrome P450 2E1 and possible modifications on
tubular reabsorption (11).
However, not only biology can explain the variability
of losing weight, other factors are associated with
the feasibility of following medical recommendations
affected by cultural environment. The importance
of lifestyle was defined in early times of weight
loss intervention but was debated by the use
of medication.
Numerous international published guidelines for antiobesity treatment consider the local disparities and cultural
differences of each geographic region. The management of
obesity relies on diverse medical specialists, health professionals
and government decisions. Primary prevention of obesity is
fundamental and requires policies for favoring spaces for
physical activity and a healthy environment. Harmonization
on treatment cannot be global but can help to tailor weight

Obesity in Mexican Americans and
Mexican Immigration
Mexican Americans are spread all over the United States, the
National Health and Nutrition Examination Surveys 1988–1994
showed children aged 4 to 17 years who were born abroad had
significantly lower prevalence of overweight / obesity compared
to Mexican American children born in the U.S. (PR = 0.77,
95% CI: 0.61, 0.96). In contrast, during 2005–2014, there was
no evidence of a difference in overweight / obesity at birth
(PR = 0.95; 95% CI: 0.84, 1.07) and no differences with newer
immigrants (<5 years living in the U.S.) compared with those
born in the U.S. (9).
Regarding the diet quality, Yoshida et al. (10) reported age
differences in diet quality influenced by acculturation (customary
adoption of a new culture): older Mexican Americans had higher
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5% loss of initial weight after 12 weeks of treatment. This guide
discusses metabolic surgery focusing on metabolic effects as
primary outcomes instead being limited to weight loss (13).
The Endocrine Society in 2015 published the guideline for
pharmacological management of obesity (14) implementing diet,
exercise, and behavioral modification and suggesting drugs may
amplify adherence to behavior change, especially for patients with
a clinical history of failure in non-medication treatments.
The nutritional health status in Mexico was affected by
government policies, the first supermarket chains selling
American processed food in Mexico started in the 1940s. The
government eliminated the subsidy of corn tortillas in 1999 with
the objective to improve competitiveness in the global economy.
This action loaded in the closure of local tortilla factories not
able to compete. The transition epidemiology from infectious
to chronic diseases was rampant in this period. In 2008 the
import tariffs on maize, bean, sugar, and mill were eliminated. In
response to the nutritional problems and increase in obesity, in
2010 the Ministries of Public Education and of Health published
the General Guidelines for Dispensing or Distribution of Foods
and Beverages at School Food Establishments (SFEs). After a
mass media campaign to reduce consumption of high caloric
food, the Mexican congress, in 2014, excised a tax on high energy
dense food (15).
The aim of our study was to perform a systematic review
with meta-analyses to synthesize and evaluate the evidence of
anti-obesity interventions on BMI and other cardiometabolic
associated traits performed in Mexican adults with overweight
and obesity. These treatments include pharmaceutical,
behavioral, surgical, nutritional, and alternative interventions
designed as controlled clinical trials, to compare results within
and between interventions.

FIGURE 2 | Study framework for systematic review with meta-analyses. The
flowchart shows the processes of collection, screening, quality assessment,
data extraction, and analysis.

loss treatments, and metabolic improvement for prevention of
complications (12, 13).
Since 2000 guidelines from the former North American
Association for Study of Obesity (nowadays The Obesity
Society—TOS) and the NIH Working Group were mainly based
on dietary therapy, physical activity, and behavioral therapy, and
guided on the appropriate use of pharmacological and surgical
interventions. The weight loss recommendation was for patients
with BMI >30 and those with BMI between 25 and ≤30 with two
or more complications. They suggested that pharmacotherapy
should be used only in the context of a treatment program with
diet, physical activity, and behavioral therapy. Once the guide
was published, only two drugs were approved for weight loss:
sibutramine and orlistat (12).
The European guidelines also made emphasis on lifestyle
modifications including nutrition and physical activity. The
goals are risk reduction (even with modest weight loss i.e., 5–
10% of initial body weight), attention on waist circumference
and management of complications. They increase the number
of drug treatments for obesity approved by FDA (Food and
Drug Administration) and EMA (European Medicines Agency):
orlistat, lorcaserin (only for FDA), phentermine/topiramate
(only for FDA), bupropion/naltrexone and liraglutide. They
recommend drug discontinuation if the patient does not reach

Frontiers in Medicine | www.frontiersin.org

METHODS
Protocol Registration and Search Strategy
The protocol was registered in PROSPERO on 11/17/2020 and
assigned the registry number CRD42020221436 (16).
The PICO Structure is as follows:
Participants/population: Mexican adults classified as
overweight or obese by WHO criteria included in controlled
clinical trials for anti-obesity interventions and randomly
allocated to treatment groups.
Interventions: Approaches conducted in the Mexican
population to treat obesity, including alternative medicine,
pharmacological, nutritional, behavioral, and surgical
interventions reporting BMI as.
Comparisons: Within and between studies comparison
of anti-obesity interventions on BMI, in addition to
cardiometabolic associated traits, in which control groups
were placebo or active treatments. Studies with at least 3 months
of treatment were included in the meta-analyses in order to
reduce the placebo effect.
Outcomes: Biometric markers associated with obesity such
as BMI, waist circumference, triglycerides, glucose, HDL-C,
diastolic, and systolic pressure.
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and gray literature, we contacted Medical Societies such as
the Endocrinology Society from Mexico and researchers
from academic institutions such as UNAM. For inclusion
in the meta-analysis, all interventions had to be conducted
for at least 3 months—as a strategy to control for placebo
effects—and report both baseline and final BMI. The query
was focused on all interventions with overweight or obese
participants who underwent weight loss treatment. We
included nutritional/behavioral treatments, with knowledge
that many of these interventions cannot be blinded, therefore
we assessed the possibility of bias using the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) approach (17). Medications, alternative medicine
and surgical interventions were included in the review finished
in December 2020.
An example of a search strategy performed in Pubmed without
time period limits:
[(“obesity”[MeSH Terms] OR “obesity”[All Fields])
AND (“therapy”[Subheading] OR “therapy”[All Fields] OR
“treatment”[All Fields] OR “therapeutics”[MeSH Terms] OR
“therapeutics”[All Fields])] AND (“mexico”[MeSH Terms] OR
“mexico”[All Fields]) AND Clinical Trial[ptyp].

TABLE 1 | Characteristics of the analyzed interventions (n = 58).
Category

N

%

References

Study design
A. Drugs

28

48.3

17 (* § ≪)

29.3

(19–33)

11 (*)

19

(34–40)

28

48.3

B1. Food and
supplements

11 (* ≪)

19

(25, 41–49)

B2. Diet

A1. Non-diabetic
patients
A2. Diabetic
patients
B. Nutrition and
exercise

6 (* ≪)

10.3

(45, 50–53)

B3. Behavioral

1 (*)

1.7

(54)

B4. Exercise

1 (*)

1.7

(55)

7 (* ≪)

12.1

(45, 46, 55–57)

2 (≪)

3.4

(58–60)

2

3.4

B5.
Multi-component
B6. Alternative
C. Surgery
C1. Cx

1 (§)

1.7

(61)

C2. Cx-diet

1 (*)

1.7

(62)

Gender†
Male

5

11.1

(20, 23, 49, 55, 59)

Female

9

20

(24, 25, 45, 46, 52, 54, 56,
58, 62)

Both

31

68.9

(19, 21, 22, 26–44, 47–51,
53, 54, 57, 60, 61, 63)

Youth (18–35
years old)

11

24.4

(19, 41, 42, 44–46, 49, 53,
62)

Young adults
(36–45 years old)

21

46.7

(20, 22–24, 28–
32, 34, 37, 38, 43, 47, 48,
51, 55–58, 63)

Older adults (46 or
more years)

13

28.9

(19, 21, 35–37, 39, 40, 52,
54, 60, 61)

México City

17

37.8

(24, 27, 30–33, 35, 36, 38,
40, 49, 54, 57, 58, 60, 61)

Guadalajara

13

28.9

(19, 20, 26, 28, 34, 37, 39,
42–44, 47, 51, 62)
(21, 22, 53)

Eligibility Criteria
The systematic review included Mexican adult overweight
or obese participants in controlled clinical trials subjected
to pharmaceutical, behavioral, surgical, nutritional, or
alternative interventions. Weight loss was the primary or
secondary outcome, besides, we included cardiometabolic
traits outcomes when available. We included studies published
in English or Spanish at any time, conducted in Mexican
centers and multicentric international studies with Mexican
participants. For inclusion in the meta-analysis, treatments
had to be conducted for at least 3 months and indicate
baseline and final BMI. When available, we analyzed
obesity-related cardiometabolic components (i.e., serum
concentration of glucose, HDL-C, triglycerides, systolic
and diastolic blood pressure, and waist circumference). We
followed these criteria for the articles’ peer-screening and
conducted a third final group review to resolve disagreements
applying an online Delphi method due to confinement in
times of COVID-19 (18). We contacted the corresponding
authors to clarify doubts and obtain additional information
when necessary.

Age†

City†

Cd. Madero

3

6.7

Cuernavaca

2

4.4

(50, 63)

Durango

2

4.4

(52, 56)

Querétaro

2

4.4

(45, 46)

Tijuana

2

4.4

(41, 59)

León

1

2.2

(55)

Monterrey

1

2.2

(29)

Studies Selection

San Luis Potosí

1

2.2

(25)

Villahermosa

1

2.2

(48)

We recovered 634 studies from three databases: Pubmed (n
= 180), Scopus (n = 238), and Web of Science (n =
216). After eliminating duplicate studies and applying the
eligibility criteria, 589 studies were eliminated. The flux of
the analyzed studies is described in Figure 2. Of the 45
included studies data were extracted using the Cochrane tool
and quality assessed with the Jadad scale. There were 45
studies included in the qualitative synthesis and 25 in the
meta-analysis. There were 55 interventions in the studies
included for the qualitative synthesis: 25 with medications,

Duration of study: (≪) < 3 months, (*) ≥3 months to 9 months, (§) ≥ 12 months. † The
frequency represents the number from 45 studies.

The search strategies included Pubmed, Scopus, and Web
of Science databases to obtain published literature up to
2019 to include randomized controlled clinical trials for
obesity conducted in Mexico. To identify additional studies

Frontiers in Medicine | www.frontiersin.org
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Nutritional and behavioral intervention
Sample
size

Intervention
implemented/
control

Number of
participants (basal,
final)

Treatment
duration

Aims/Outcomes

Significance difference between
groups

Moran (57)
Mexico City
1997

Male and Female
Intervention: 39 ± 15;
Control: 38 ± 10 years old.
BMI ≥30 Kg/m2

36

Intervention: diet +
750 mg
ursodeoxycholic acid
(AUD) + fiber placebo
Control: diet + 15 g
Plantago psyllium (pp)
+ AUD placebo

Intervention: 18, 18
Control: 18, 18

2 months

Primary: prevention of gallstone disease
(GD) in obese subjects undergoing a
weight-reduction diet. Cholesterol
crystals in duodenal bile were used as
surrogate of GD risk

Yes: Treated individuals had less presence
of cholesterol crystals

RodriguezHernandez (56)
Durango
2009

Female
45.4 ± 10.4 years old
BMI ≥30 Kg/m2

105

Intervention:
Cognitive behavioral
treatment + Low carb
diet or low- fat diet
Control: Non cognitive
behavioral treatment

Intervention: 55, 52
Control: 50, 50

6 months

Primary: weight loss
Secondary: Depression and anxiety,
fasting glucose and triglycerides

Yes: CBT-LF had significant differences
were observed in waist circumference,
weight, and BMI in the and significantly
decreased body fat, weight, BMI and
triglycerides compared with C-LF group

Ble-Castillo (48)
Tabasco
2010

Male and Female
51.7 ± 5.6 years old BMI
≥30 Kg/m2 T2DM

30

Intervention: Native
Banana Starch
Control: Soy Milk

Intervention: 15, 14
Control: 15, 14

2 months

Primary: Body weight and insulin
sensibility
Secondary: Cholesterol; HDL;
Triglycerides; Diastolic blood pressure;
Systolic blood pressure; Waist to hip
ratio; Calcium; Phosphates

Yes: Body weight, BMI, waist to hip ratio
and triglycerides significantly reduced
No: No significant changes in glucose and
HbA1c. A decrease in serum triglycerides
in control group. No changes were
observed on calcium, phosphate and
hematological markers such as white
blood cells, platelets and other indexes

RodriguezHernandez (52)
Durango
2011

Female
Intervention: 46.3 ± 9.1;
Control: 45 ± 9.1 years old
BMI ≥30 Kg/m2 NAFLD

59

Intervention: low
carbs diet (LCD)
Control: low fat
diet (LFD)

Intervention: 31, 28
Control: 28, 26

6 months

Primary: To evaluate decrease
aminotransferase levels.

No: No significant differences in
anthropometric and biochemical
characteristics between groups

Rosado (46)
Queretaro
2011

Female
34 ± 6 years old
BMI ≥30 Kg/m2

139

Intervention 1: 46, 33
Intervention 1: Low
Intervention 2: 46, 37
fat milk
Control: 47, 31
Intervention 2: Low
fat milk with
added micronutrients
Control: No milk intake

4 months

Primary: To evaluate anthropometrics,
body composition, blood glucose levels,
lipids profile, C-reactive protein, and
blood pressure

Yes: LFM+M group lost significantly more
weight than control group. BMI in the
LFM+M group was significantly greater
than LFM group members and Control
group. Body fat among LFM+M group
members was significantly higher than
LFM and control group
No: No differences between groups in
glucose level, blood lipid profile, blood
pressure, or C-reactive protein level

Madero (53)
Mexico City
2011

Male and female
Intervention 1: 37.56 ±
1.14; Intervention 2: 40.15
± 1.01 BMI > 25 Kg/m2

131

Intervention 1: Low
fructose diet
Intervention 2:
Moderate natural
fructose diet

1.5 months

Primary: weight loss
Secondary: Blood pressure, lipid profile,
serum glucose, insulin resistance, uric
acid, soluble intercellular adhesion
molecule-1, and quality of life scores

Yes: Significant weight loss compared with
baseline in both treatments, but higher in
the MNF group. Significant improvement in
secondary outcomes in both treatments

November 2021 | Volume 8 | Article 665023

Intervention 1: 65, 65
Intervention 2: 66, 66

(Continued)
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Participants

6

Author
State
Year
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TABLE 2 | Descriptive characteristics and assessment of nutrition/behavioral interventions.

Nutritional and behavioral intervention
Sample
size

Intervention
implemented/
control

Number of
participants (basal,
final)

Treatment
duration

Aims/Outcomes

Significance difference between
groups

Tovar (45)
Queretaro
2012

Female
Intervention 1: 34.62 ± 7.4;
Intervention 2: 33.17 ±
7.63;
Intervention 3: 32.58 ±
8.13;
Control: 33.39 ± 8.72
years old.
BMI ≥ 25 Kg/m2

144

Intervention 1: Partial
meal replacement
(PMR) + Inulin (INU)
Intervention 2: PMR
Intervention 3: INU
Control: No
additional treatment

Intervention 1: 36, 23
Intervention 2: 36, 28
Intervention 3: 36, 30
Control: 36, 29

3 months

Primary: weight reduction, blood lipids
and micronutrients

Yes: all groups significantly reduced BMI,
weight, waist and hip circumference.
Subjects in PMR+INU, PMR and INU
significantly decreased triglycerides Fiber
intake increased in PMR+INU and INU
groups. In PMR and PMR+INU groups
some minerals and vitamins intakes
increased compared with INU and
control groups

Martinez-Abundis
(44)
Jalisco
2013

Male and female
Intervention: 35.4 ± 4.3;
Control: 35.4 ± 3.8
years old.
BMI 30–39.9 Kg/m2

14

Intervention: Avocado
Soybean
Unsaponifiable (ASU)
Control: Placebo

Intervention: 7, 7
Control: 7, 7

3 months

Primary: Glucose, triglycerides, HDL-C,
leptin, C-reactive protein (CRP), TNFα,
adiponectin, erythrocytes, fatty acids and
metabolic syndrome

No: Without significant differences
between groups before and after the two
treatments in hs-CRP, IL-6, insulin
secretion, and insulin sensitivity

Perichart-Perera
(54)
Mexico City
2014

Postmenopausal Female
Intervention: 54.81 ± 6.38;
Control: 52.65 ± 6.35
years old.
BMI ≥ 25 Kg/m2 MetS

118

Intervention:
Behavioral therapy
Control: Structured
hypocaloric diet

Intervention: 55, 55
Control: 63, 63

6 months

Primary: metabolic syndrome
Secondary: weight, waist circumference,
systolic and diastolic blood pressure,
cholesterol, triglycerides, body fat mass

Yes: Higher reduction in MetS prevalence
in BT group. Significant decrease in weight
and waist circumference in both groups.
Control group significantly decreased
systolic and diastolic blood pressure, and
fat mass measurements. Control group
decrease total cholesterol and triglyceride

HernandezCordero (63)
Morelos
2014

Women
Intervention: 33.5 ± 6.7;
Control: 33.3 ± 6.7
years old.
BMI ≥ 25 Kg/m2 MetS

240

Intervention: Water
and Education
provision (WEP)
Control: Education
Provision (EP)

Intervention: 120, 102 9 months
Control: 120, 87

Primary: to determine if replacing SSBs
with water affects plasma triglycerides
(TGs), weight, and other cardiometabolic
factors

No: No effect on plasma TGs, weight, and
other cardiometabolic risks in the ITT
analysis

Macias-Cervantes
(55)
Guanajuato
2015

Male
Intervention 1: 40 ± 4.8;
Intervention 2: 43.5 ± 7.1;
Intervention 3: 44.3 ± 5.3
years old.
BMI ≥ 25 Kg/m2

43

Intervention 1: Low
AGE diet
Intervention 2:
Exercise with regular
food intake
Intervention 3:
Exercise with low
AGE diet

Intervention 1: 14
Intervention 2: 14
Intervention 3: 15

3 months

Primary: Identify the effect of a low
advanced glycation end product (AGEs)
diet, exercise, and a combination of both
on circulating AGE levels as well as on
plasma lipids and anthropometric
parameters. Secondary: blood pressure,
beats per minute, Diet-Cal, fasting blood
glucose, HDL-C, heart rate,
LDL-Cholesterol, VO2 (oxygen
consumption)

Yes: in the group with low AGE diet were
differences in weight, BMI, waist
circumference, serum AGEs Group with
normal diet + exercise: weight, BMI, waist
circumference, heart rate max
and VO2 max In group with low AGE diet
+exercise: weight, BMI, waist,
triglycerides, HDL, LDL, serum AGEs,
and VO2 max

Romero-Prado
(51)
Jalisco
2015

Male and female
42.2 ± 7.5 years old BMI
25–34.9 Kg/m2
Hypertension according to
WHO criteria

110

Intervention:
Flavonoids Diet +
Anti-hypertensive
therapy (Captopril/
Telmisartan)

Intervention; 40, 40
Control: 70, 39

6 months

Primary: blood pressure, lipid profile,
obesity and inflammation

Yes: SBP, DBP, cholesterol and
triglycerides, BMI, waist circumference
and CRP showed differences at 3 and 6
months in the intervention group. HDL only
when comparing baseline and 6 months
No: Leptin levels
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Author
State
Year

Participants

Sample
size

Intervention
implemented/
control
Control:
Anti-hypertensive
therapy (captopril/
Telmisartan)
Intervention:
High-Protein Diet
Control:
Standard-Protein Diet

8

Treatment
duration

Aims/Outcomes

Significance difference between
groups

Intervention: 59,59
Control: 59, 46

6 months

Primary: Evaluate the effect of increased
protein intake on weight loss in adults
with MetS
Secondary: (all measured in baseline, 3
and 6 months): fasting blood glucose,
fasting insulin, hemoglobin A1c, total
cholesterol, high-density lipoprotein (HDL)
cholesterol, very-low-density lipoprotein
(VLDL) cholesterol, triglycerides,
C-reactive protein, creatinine, blood urea
nitrogen, alanine aminotransferase,
aspartate aminotransferase, and
gamma-glutamyl transferase
Primary: Evaluate the genoprotective
effect of consuming a flavonoids-rich
chocolate
Secondary: Biochemical parameters
related to cardiovascular risk and
metabolic syndrome: changes in BMI,
waist circumference, Fasting plasma
glucose, HOMA, HbA1c, Systolic blood
pressure, Diastolic blood pressure,
Cholesterol total, triglyceride, Nuclear
Abnormalities in Buccal Epithelial Cells
Primary: Effects of agave fructans on
weight control, lipid profile, and physical
tolerability. Weight, hip, waist, hip waist
index, total body fat (%), glucose, serum
insulin, total cholesterol, (HDL) and (LDL)
cholesterol, triglycerides
Secondary: Safety assessments were
performed Weight, hip, waist, hip waist
index, total body fat (%), glucose, serum
insulin, total cholesterol, HDL and LDL
cholesterol, triglycerides

Yes: Decreased weight, % of
abdominal fat Differences observed in
both groups: waist circumference, Systolic
blood pressure, fasting blood glucose,
insulin, HOMA index, triglycerides, total
cholesterol, VLDL cholesterol. The group
SDP, presented a difference in HDL and
direct bilirubin

Campos-Nonato
(50)
Morelos
2017

Male and female
47.4 ± 11.5 years old BMI
25–45 Kg/m2 MetS

118

Leyva-Soto (41)
Baja California
2018

Male and female
Intervention: 23.8 ± 3.4;
Control: 23.6 ± 3.5
years old BMI > 29 Kg/m2
MetS

92

Intervention:
Dark chocolate
Control:
Milk Chocolate

Intervention: 42, 42
Control: 50, 42

6 months

Padilla-Camberos
(42)
Jalisco
2018

Male and female
20-55 years old BMI >
30 Kg/m2

28

Intervention: 14, 14
Intervention:
Control: 14, 14
Agave fructan
s Control: Maltodextrin

3 months

Yes: abnormalities of the nuclei in the
buccal epithelial cells decreases
significantly (<2%) after 6 months of daily
consumption of 2 g of dark chocolate.
Decreased BMI, waist circumference, Total
cholesterol, LDL Cholesterol, triglycerides,
HOMA-IR, fasting plasma glucose, systolic
and diastolic blood pressure in the group
commercial dark chocolate

Yes: BMI and triglycerides of the Agave
fructans treated group was reduced
significantly from the baseline to the final
measurements. Hip and waist
circumference decreased in both groups
No: Glucose values

AUD: ursodeoxycholic acid; PP: Plantago psyllium; GD: gallstone disease; CBT-LF: Cognitive behavioral treatment with low- fat diet; C-LF: control group with low-fat diet; BMI: Body mass index; TG: Triglycerides; SBP: Systolic
Blood Pressure; DBP: Diastolic Blood Pressure; A1c: 0Glycated hemoglobin; HDL-c: High density lipoprotein cholesterol; LDL-c: 0Low density lipoproteins cholesterol; VLDL-c: Very low density lipoprotein cholesterol; CRP: C-reactive
protein; LFM: Low fat milk; LFM+M: Low fat milk with added micronutrients; IR: insulin resistance; MNF: Moderate natural fructose diet; PMR: Partial meal replacement; INU: Inulin; ASU: Avocado Soybean Unsaponifiable; TNF-a:
Tumor0Necrosis0Factor0alpha; hs-CRP: High-sensitivity C-reactive Protein; IL-6: Interleukin-6; MetS: Metabolic0syndrome; BT: Behavioral therapy; WEP: Water and Education provision; EP: Education Provision; SSBs: Sugar-Sweetened
Beverages ITT: Insulin tolerance test; AGEs: Advanced glycation end products; VO2: oxygen consumption; VO2max: HOMA: Homeostatic Model Assessment; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance.
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implemented/control
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participants (basal,
final)

Treatment
duration

Aims/Outcomes

Significance difference
between groups

Fanghänel (36)
Mexico City
1996

Male and Female
Intervention: 52.1 ± 8.8;
Control: 51.2 ± 8.5
years old.
BMI > 27 Kg/m2 NIDDM

60

Intervention: Metformin
Control: Insulin

Intervention: 30, 28
Control: 30, 30

3 months

Primary: glucose and lipid
metabolism
Secondary: Glycosylated
hemoglobin, BMI, blood pressure

Yes: Metformin had beneficial
effects on insulin resistance,
hypertension, overweight, and
hyperlipidemia

Fanghänel (35)
Mexico City
1998

Male and Female
Intervention: 49.3 ± 9.6;
Control: 47.1 ± 7.3
years old.
BMI >27 T2DM

120

Intervention:
Metformin, Insulin Control:
Diet

Intervention: 60, 60
Control: 60, 60

3 months

Primary: levels fibrinogen.

Yes: The insulin group showed
decrease on glucose, fibrinogen
levels and BMI

Cuellar (31)
Mexico City
2000

Male and female
Intervention: 38.44 ± 10.09;
Control: 38.62 ± 9.12
years old.
BMI >30 Kg/m2

69

Intervention: Sibutramine
Control: Placebo

Intervention: 35, 22
Control: 34, 9

6 months

Primary: Safety and efficacy of
sibutramine
Secondary: waist circumference
and waist/hip ratio. Appetite,
satiety, and diet adherence were
also evaluated

Yes: Sibutramine induces
significant loss of body weight
and waist circumference. No
significant adverse events.
NOTE: Sibutramine was
withdrawn in 2010

Fanghänel (32)
Mexico City
2000

Male and female
Intervention: 38.09 ± 10.11;
Control: 39.48 ± 10.26
years old.
BMI >30 Kg/m2

109

Intervention: Sibutramine
Control: Placebo

Intervention: 55, 40
Control: 54, 44

6 months

Primary: Safety and efficacy of
sibutramine 10 mg
Secondary: Waist circumference
and waist/hip ratio, blood
pressure and heart rate and
clinical laboratory

Yes: Sibutramine induces
significant loss of BMI and waist,
but does not significantly affect
cardiovascular function. No
significant adverse events.
NOTE: Sibutramine was
withdrawn in 2010

Fanghänel (33)
Mexico City
2001

Male and female
Intervention: 40.1 ± 10.51;
Control: 39.0 ± 10.15
years old.
BMI >30 Kg/m2

82

Intervention: Sibutramine
Control: Placebo

Intervention: 40, 40
Control: 44, 42

6 months

Primary: Endpoints for the trial
were the body weight and BMI
Secondary: Endpoints were the
waist and waist/hip ratio,
appetite, satiety and diet
adherence and adverse events

Yes: Patients had weight gain,
but they did not reach the
baseline body weight. No
significant adverse events.
NOTE: Sibutramine was
withdrawn in 2010

Zaragoza (30)
Mexico City
2001

Male and Female
Intervention 1: 36.84 ±
9.16;
Intervention 2: 36.79 ±
10.61;
Control: 36.77 ± 9.18
years old
BMI > 30 Kg/m2

210

Intervention 1:
D-norpseudoephedrine
50 mg, triiodothyronine 75
ug, diazepam 5 mg, atropine
0.36 mg, aloin 16.2 mg
Intervention 2:
D-norpseudoephedrine
50 mg, atropine 0.36 mg,
aloin 16.2 mg
Control: Placebo

Intervention 1: 69, 59
Intervention 2: 70, 51
Control: 69, 26

6 months

Primary: Update data on the
efficacy and safety of two
formulations of
d-norpseudoephedrine in
prolonged-release capsules,
which have been used
successfully in the treatment of
obesity since 1956 and 1995

Yes: The efficacy and safety of
formulations 1 and 2 in the
pharmacological treatment of
obesity are confirmed, these
d-norpseudoephedrine
formulations maintain the weight
reduction achieved for periods of
at least 6 months, without
causing addiction or inducing
tolerance with loss of
effectiveness after a shorter
period. NOTE: Not approved by
FDA
(Continued)
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Pharmacological intervention
Sample
size

Intervention
implemented/control

Number of
participants (basal,
final)

Treatment
duration

Aims/Outcomes

Significance difference
between groups

Halpern (40)
Multinational
2003

Male and Female
Intervention: 50.88 ± 1.37;
Control: 50.79 ± 1.48
years old.
BMI> 27 Kg/m2 NIDDM

343

Intervention: Orlistat
Control: Placebo

Intervention:169, 139
Control: 174, 141

6 months

Primary: To determine if obese
non-insulin-dependent diabetic
patients lose more weight when
treated for 24 weeks with orlistat,
in conjunction with a hypocaloric
diet plus behavioral counseling,
than when treated by placebo
plus similar instructions
Secondary: To evaluate the
effects on glucose profile and to
determine the tolerability and
safety of orlistat

Yes: Orlistat group lost greater
body weight vs. in the placebo
group, Orlistat treatment plus
diet compared to placebo plus
diet was associated with
significant improvement in
glycemic control, as reflected in
decreases in HbA1c, fasting
plasma glucose and postprandial
glucose and greater
improvements than placebo in
lipid profile, with reductions in
total cholesterol and LDL-c

Gonzalez-Ortiz
(39)
Jalisco
2004

Male and Female
Intervention 1: 53 ± 8;
Intervention 2: 53 ± 7;
Intervention 3: 53 ± 7
years old.
BMI >27 Kg/m2
T2DM with A1c > 8%

104

Intervention 1: Glimepiride
Intervention 2: Metformin
Intervention 3: Glimepiride
+ Metformin

Intervention 1: 37, 37
Intervention 2: 33, 33
Intervention 3: 34, 34

3 months

Primary: To evaluate the efficacy
and safety of glimepiride plus
metformin in a single presentation,
as combined therapy, in patients
with T2DM with secondary failure
to glibenclamide

Yes: The percentage of patients
that improved A1C levels to <7%
were in glimepiride, metformin
and their combination groups

Gómez-García (49)
Jalisco
2006

Male
Intervention: 21.8 ± 2.8;
Control: 25.1 ± 4.5
years old.
BMI ≥27 Kg/m2

14

Intervention: Zinc sulfate
Control: placebo

Intervention: 7, 7
Control: 7, 7

30 days

Primary: Insulin sensitivity, leptin
and androgens
Secondary: Glucose, total
cholesterol, HDL-c, LDL-c,
VLDL-c, triglycerides, creatinine,
uric acid, TT, TL, SHBG

Yes: Zinc increased the leptin
concentrations in obese
No: No significant changes in
insulin sensitivity and androgens
after the intervention

Toplak (29)
Multinational
2005

Male and female
Intervention 1: 41.3 ± 11.0;
Intervention 2: 41.1 ± 12.1
years old.
BMI 30–43 Kg/m2

430

Intervention 1: Orlistat +
Diet−500 kcal
Intervention 2: Orlistat +
Diet -1000kcal

Intervention 1: 215,
141
Intervention 2: 215,
154

12 months

Primary: To determine the effect
of two different levels of energy
deficit on weight loss in obese
patients treated with orlistat

No: Treatment with orlistat was
associated with a clinically
beneficial weight loss,
irrespective of the prescribed
dietary energy restriction

Gonzalez-Ortiz
(28)
Jalisco
2006

Male and Female
Intervention: 37.3 ± 6.7;
Control: 38.5 ± 5.8
years old.
BMI: 25–35 Kg/m2
Dyslipidaemia

12

Intervention: Ezetimibe
Control: Placebo

Intervention: 6, 6
Control: 6, 6

3 months

Primary: To evaluate the effect of
ezetimibe on insulin sensitivity and
lipid profile in obese and
dyslipidemic patients

Yes: Ezetimibe administered for
90 days decreased total and
low-density lipoprotein
cholesterol concentrations
No: Insulin sensitivity

Meaney (27)
Mexico City
2008

Male and female
Intervention: 49 ± 10;
Control: 49 ± 8 years old.
MetS

60

Intervention: Metformin
Control: Diet

Intervention: 30, 22
Control: 28, 17

12 months

Primary: To evaluate the effect of
metformin on metabolic
syndrome in IGT patients

Yes: Metformin has effect on
endothelial function
and nitroxidation
No: No-effect on BMI
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Treatment
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Aims/Outcomes

Significance difference
between groups

HernandezGonzalez (47)
Jalisco
2010

Male and Female
Intervention: 41.6 ± 6.3;
Control: 42.6 ± 5.6
years old.
BMI: 30–40 Kg/m2
Without DM

12

Intervention: Chitosan
Control: Placebo

Intervention: 6, 6
Control: 6, 6

3 months

Primary: Insulin sensitivity
Secondary: Glucose, HDL-c,
LDL-c and triglycerides

Yes: Increased insulin sensitivity
and decrease weight, BMI, waist
circumference and TG

Martinez-Abundis
(26)
Jalisco
2010

Male and female
Intervention 1: 29.5 ± 6.3;
Intervention 2: 26.1 ± 4.0;
Intervention 3: 29.6 ± 5.5
years old.
BMI 30–40 Kg/m2

18

Intervention 1: Placebo
and metformin
Intervention 2: Sibutramine
and placebo
Intervention 3: Sibutramine
and metformin

Intervention 1: 9, 9
Intervention 2: 9, 9
Intervention 3: 9, 9

3 months

Primary: To compare the effect of
metformin and sibutramine as
monotherapy or as combined
therapy on insulin sensitivity and
adiposity in obese patients
Secondary: To evaluated Blood
pressure, ITT, glucose, total
cholesterol, LDL-c, HDL-c,
triglycerides

Yes: The three pharmacological
interventions reduced BMI at
different magnitudes. Metformin
improved insulin sensitivity.
Sibutramine decreased adiposity.
Metformin as monotherapy or
combined with sibutramine had
a beneficial effect on lipid profile

Ramos-Zavala (34)
Jalisco
2011

Male and female
Intervention: 47.5 ± 5.3;
Control: 47.7 ± 5.2
years old.
BMI > 25 T2DM with <6
months since diagnosis

40

Intervention: Diacerein
Control: Placebo

Intervention: 20, 20
Control: 20, 20

2 months

Primary: Insulin secretion and
metabolic control (included
interleukin IL-Iß, TNF-a, IL-6)

Yes: Significant increases in first,
late and total insulin, fasting
glucose and A1C levels,
TNF-a, IL-6
No: Without significant
differences in total cholesterol,
HDL-c, LDL-c, triglycerides,
VLDL-c and metabolized glucose

GonzálezAcevedo (25)
San Luis Potosi
2013

Women
Intervention 1: 31.65 ±
7.41;
Intervention 2: 28.45 ±
8.15;
Control: 30.70 ± 6.87
years old
BMI > 30 Kg/m2

60

Intervention 1: 1 g
of Omega-3
Intervention 2: 2 g
of Omega-3
Control: Placebo+ Vitamin
E (200 IU)

Intervention 1: 20, 20
Intervention 2: 20, 20
Control: 20, 20

3 months

Primary: To assess the effect of
omega-3 supplementation on
BMI, WHI and body composition
of obese women using
bioelectrical impedance

Yes: Supplementation
significantly reduced weight,
BMI, and total fat mass,
compared to the control group, a
dose-response effect, but these
effects depended on the time
and amount of Omega 3
supplemented, when the degree
of compliance of exercise,
adherence to the diet and age
were controlled

Sánchez-Muñoz
(24)
Mexico City
2013

Women
25–60 years old
BMI >24,9 Kg/m2

19

Intervention: Metformin
Control: Exercise

Intervention: 9, 8
Control: 10, 8

3 months

Primary: To establish the
effectiveness of aerobic exercise
and its influence in reducing
cardiovascular risk in overweight
or obese women with NAFLD.

Yes: It was significative changes
in Arterial tension, HOMA-IR
and insulin
No: Was not significative
differences in fatty liver
(Continued)
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HernandezCorona (43)
Jalisco
2014

Male and female
Intervention: 45.4 ± 7.3;
Control: 42.4 ± 3.7
years old.
BMI: 25–34.9 Kg/m2

25

Intervention: F Fucoidan
Control: Placebo

Intervention: 13, 11
Control: 12, 8

3 months

Primary: Evaluate changes in
insulin secretion and insulin
resistance.
Secondary: Weight, blood
pressure, glucose, total
cholesterol, HDL-c, TG and IR.

Yes: Significant decrease in DBP
and LDL-c, Increase in insulin
levels, HOMA B-cells and
HOMA IR
No: BMI

HernandezBastida (38)
Mexico City
2015

Male and female 18–65
years old BMI 25–40 Kg/m2
T2DM

120

Intervention: Topiromate
+ Phentarmine Control:
Placebo + Phentarmine

Intervention: 60, 54
Control: 60, 53

3 months

Primary: Efficacy and safety of
the combination of phentermine
plus topiramate
Secondary: To evaluate the
impact of the combination over
risk and safety factors

Yes: The combination showed
reduction in weight, BMI, waist,
circumference, lipids and
glucose. The most frequent
adverse events were paresthesia
and dry mouth, these effects
decreased in frequency and
intensity during the study

O’Neil (22)
Multinational
2016

Male and female
Hispanic Age: Intervention:
41.4 ± 11.4;
Control: 41.0 ± 11.7
years old
BMI ≥27 Kg/m2 with at
least 1 comorbid condition
or BMI ≥30 Kg/m2

5,131
Hispanic:
534

Intervention: Liraglutide
Control: Placebo

Intervention: 3,289,
3,289
Control: 1,842, 1,842
Hispanic
participants:
Intervention: 341, 341
Control: 193, 193
(their data were
combined with other
ethnic groups)

3 studies of
56 weeks 1
study of
32 weeks

Primary: Efficacy and safety of
liraglutide
Secondary: Weight and risk
factors

Yes: Efficacy and safety were
largely similar between Hispanic
and non-Hispanic

SánchezRodriguez (23)
Mexico City
2016

Healthy postmenopausal
women or with MetS.
Healthy women:
Intervention: 52 ± 0.6;
Control: 53 ± 0.7 years old.
MetS women: Intervention:
52 ± 0.7;
Control: 53 ± 0.9 years old.

100

Intervention:
Hormone therapy Control:
Placebo

Intervention: 50, 46
Control: 50, 45

6 months

Primary: Oxidative stress

Yes: After 6 months, MetS
decreased in the hormone
treated group (48%), triglycerides
and HDL-c; the controls did not
show differences. SS in MSW-HT
decreased (3.8 ± 0.3 to 1.7 ±
0.3, p < 0.05) and Oxidative
stress was also reduced (44%),
this effect was evident since 3
mo. HW-HT with high OS also
decreased (40%) In placebo
groups there was no change
(Continued)
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Mendez-del Villar
(37)
Jalisco
2017

Male and Female
Intervention: 41.3 ± 9.7;
Control: 54 ± 3.5 years old.
BMI: 25-34.9 Kg/m2
T2DM and inadequate
glycemic control

12

Intervention: Metformin
+ Diacerein Control:
Metformin

Intervention: 6, 6
Control: 6, 6

3 months

Primary: Glycemic control

Yes: Significant decrease in
fasting glucose, postprandial
glucose and A1C

Gonzalez-Heredia
(19)
Jalisco
2017

Male and female
Intervention: 49.3 ± 5.7;
Control: 51.9 ± 6.4
years old. BMI
25–34.9 Kg/m2 Impaired
Glucose Tolerance

16

Intervention: Linagliptin
Control: Metformin

Intervention: 8, 8
Control: 8, 8

3 months

Primary: To assess the effect of
linagliptin vs. metformin on
glycemic variability in patients with
IGT

Yes: Group with linagliptin had
decrease in glucose levels at
120 min of OGTT
No: No significant differences in
the AUC, MAGE, SD of glucose,
CV of glucose, and MBG
between groups

Gonzalez-Ortiz
(20)
Jalisco
2017

Male
Intervention: 40.2 ± 7.9;
Control: 38.4 ± 6.4
years old. BMI
30–39.9 Kg/m2

18

Intervention: Taladafil
Control: Placebo

Intervention: 9, 9
Control: 9, 9

28 days

Primary: Blood pressure,
cholesterol, triglycerides, HDL-c,
LDL-c, glucose

No: After the administration of
tadalafil there were no significant
differences in total insulin
secretion first phase of insulin
secretion and insulin sensitivity.
No significant differences were
shown in other measurements

Le Roux (21)
Multinational
2017

Male and female
Intervention: 47.5 ± 11.7;
Control: 47.3 ± 11.8
years old. BMI ≥27 Kg/m2
Dyslipidemia, or
hypertension, or both

2,254
Hispanic:
213

Intervention: Liraglutide
Control: Placebo

Intervention: 1,505,
783
Control: 749, 327
Hispanic participants
Intervention: 143
Control: 70 (their data
were gathered with
other individuals)

40 months
(3.3 years)

Primary: Evaluate the proportion
of individuals with prediabetes
who were diagnosed with type 2
diabetes
Secondary: GLP-1 receptor
agonist, waist circumference (cm),
glycated hemoglobin (%), 2-h
plasma glucose during OGTT
(mmol/L), Free fatty acids
(mmol/L), Blood pressure (mm
Hg)

Yes: Time to onset of diabetes
over the 40 months among all
randomized individuals was 2·7
times longer with liraglutide than
with placebo Greater weight loss
than placebo at month 40: BMI,
waist circumference, glycated
hemoglobin, fasting glucose,
fasting insulin, fasting C-peptide,
glucose levels in OGTT, systolic
and diastolic blood pressure,
and heart rate

NIDDM, Non-insulin dependent diabetes mellitus; BMI, Body mass index; T2DM, Type 2 diabetes mellitus; FDA, Food and Drug Administration; A1c, Glycated hemoglobin; HDL, High density lipoprotein; LDL, Low density lipoproteins;
VLDL, Very low density lipoprotein; TT, Total testosterone, TL, Free testosterone, SHBG, Sex Hormone Binding Globulin; MetS, Metabolic syndrome; IGT, Impaired glucose tolerance; TG, Triglycerides; ITT, Insulin tolerance test; IL-Iß,
Interleukin 1 beta; IL-6, Interleukin-6; TNF-a, Tumor Necrosis Factor alpha; WHI, Waist Hip Index; NAFLD, Non-alcoholic fatty liver disease; IR, Insulin resistance; HOMA-IR, Homeostasis model assessment of IR; HOMA B-cells,
Homeostatic Model Assessment-beta-cell function; SS, Stress score; MSW-HT, MetS women were assigned to HT (hormone therapy); HW-HT, Healthy-hormone therapy; OS, Oxidative stress; OGTT, Oral glucose tolerance test; AUC,
Area under the curve; MAGE, Mean amplitude of glycemic excursion, SD, Standard deviation; CV, Coefficient of variation; MBG, Mean blood glucose; GLP-1, Glucagon-like peptide-1.
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TABLE 4 | Descriptive characteristics and assessment of medications.
Surgical and alternative intervention

14

Participants

Sample
size

Intervention
implemented/Control

Number of
participants
(basal, final)

Treatment
duration

Aims/Outcomes

Significance difference
between groups

Robles-Cervantes
(62)
Jalisco
2007

Female
Intervention: 34.0 ± 3.7;
Control: 34.6 ± 3.6
years old.
BMI: 30–33 Kg/m2

12

Intervention: Liposuction
and diet Control: Diet

Intervention: 6, 6
Control: 6, 6

6 months

Primary: Visceral fat, Insulin
sensitivity, leptin and tumor
necrosis factor alfa
Secondary: Glucose, Creatinine,
Uric acid, Total cholesterol, HDL
cholesterol, Triglycerides

Yes: Leptin correlated with the
subcutaneous fat
No: no significant difference in
insulin sensitivity and did not
correlate with subcutaneous fat,
leptin, or TNF-alpha

Arceo-Olaiz (61)
Mexico City
2008

Male and Female
Intervention: 36.5 ± 9.7;
Control: 37.8 ± 9.6
years old.
BMI: 40–55 kg/m2

60

Intervention: Laparoscopic
roux- en - y gastric
bypass (LRYGB)
Control: banded
LRYGB (BLRYGB)

Intervention: 30, 30
Control: 30, 30

24 months

Primary: Weight loss

No: The studied groups did not
have significant differences in
weight loss at 6, 12, and 24
months. The frequency of
complications was similar in both
groups

García-Vivas (58)
Durango
2014

Women
18–45 years old
BMI ≥25 Kg/m2
Without known MetS

138

Intervention: Acupuncture
Control:
Sham Acupuncture

138, 99

2 months

Primary: anthropometric and
biochemical

Yes: Acupoint catgut embedding
therapy + moxibustion produced
significant reduction in body
weight insulin and HOMA-IR

Alvarado-Reynoso
(60)
Mexico City
2019

Male and Female
Intervention: 42.1 ± 3.2;
Control: 37.8 ± 3.3
years old.
BMI≥ 25 Kg/m2

45

Intervention: repetitive
transcranial magnetic
stimulation) rTMS
Control: sham rTMs

Intervention: 22, 18
Control: 23, 19

2 weeks

Primary: body weight, food
craving, auto perception, general
health, depression and anxiety

Yes: In the rTMS-treated group
reduced body weight, anxiety,
and food craving. General health
survey domain improved on
physical functioning, emotional
role, and vitality. The body shape
questionnaire improved

Hernandez-Lepe
(59)
Chihuahua
2019

Male
25 ± 5 years old
BMI >25 Kg/m2
Sedentary

52

Intervention:
spirulina maxima Control:
placebo

Intervention: 26, 26
Control: 26, 26

3 months

Primary: plasma lipid profile and
antioxidant capacity

Yes: BMI, total cholesterol,
triglycerides and LDL-C
decreased. HDL-C increased in
all treatment groups. Participants
with known dyslipidemia had
higher response

HDL-c: High density lipoprotein cholesterol; LDL-c: 0Low density lipoproteins cholesterol; TG: Triglycerides; TNF-a: Tumor0Necrosis0Factor0alpha; LRYGB: Laparoscopic roux- in - y gastric bypass; BLRYGB: banded LRYGB; HOMA-IR:
Homeostatic Model Assessment for Insulin Resistance; rTMS: Repetitive transcranial magnetic stimulation; BMI: Body mass index.
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FIGURE 3 | Pooled analysis of Cohen’s d-weighted effect size on BMI reduction with nutritional and behavioral interventions. The analysis was stratified by placebo or
active comparator. LFDT, Low fat diet; LCD, Low carbohydrate diet; CBT, Cognitive-behavioral therapy; Phys Act, Physical activity; Dark Choc, Dark chocolate; AGE,
Advanced glycation end-product; Hipocal, Hypocaloric diet; WEP, Water and Education Provision; LFM, Low fat milk; Micronut, Micronutrients; PMR, Partial meal
replacement; AntiBP, Antihypertensive medication; REML, Restricted maximum likelihood.

27 with nutrition and exercise, and 3 with surgical treatment
(Table 1).

intervention (nutritional programs, behavioral treatments,
use of drugs, surgical interventions or alternative medicine), age
of intervention (childhood, adult), duration of treatments, year of
the study development, sample size, groups of intervention and
control, blindness of the treatment and the size of effects obtained
in each study (Cohen’s d). Data extraction was performed in
duplicate, and cases of discrepancy were re-analyzed in groups of

Data Extraction Process
The data extraction from the studies was done, by a team
of 13 researchers, with a modified Cochrane tool for data
collection form to obtain detailed information: type of

Frontiers in Medicine | www.frontiersin.org
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FIGURE 4 | Pooled analysis of Cohen’s d-weighted effect size on waist circumference with nutritional and behavioral interventions. The analysis was stratified by
placebo or active comparator. LFDT, Low fat diet; LCD, Low carbohydrate diet; CBT, Cognitive-behavioral therapy; Phys Act, Physical activity; Dark Choc, Dark
chocolate; AGE, Advanced glycation end-product; Hipocal, Hypocaloric diet; LFM, Low fat milk; Micronut, Micronutrients; PMR, Partial meal replacement; REML,
Restricted maximum likelihood.

The quality assessment of the studies was done using the Jadad
scale (64) and the risk of bias was assessed with GRADE checklist
(17) with the following assessment guidelines:
Low risk studies were treated with unpredictable allocation:
A central office for allocation by phone, web, and pharmacy.
Use of sequentially numbered, sealed, opaque envelopes. The
drug containers are sequentially numbered and identical.
Meanwhile high risk is predictable allocation, like staff know
the random sequence in advance. Another high risk of bias
was the use of envelopes or packaging without safeguards

4 investigators. When necessary, the authors were contacted to
collect additional information. The main outcome was related to
the reduction of BMI, waist circumference or percentage of body
fat and biochemical parameters associated with metabolism such
as glucose, total cholesterol, triglycerides, HDL-c, blood pressure,
HOMA-IR and Matsuda. We used meta-regression to analyze
the source of heterogeneity with mean age, mean BMI, location
of the study (represented as latitude of the city of recruitment),
sex distribution, and duration of the study. Adverse effects were
also analyzed.

Frontiers in Medicine | www.frontiersin.org
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FIGURE 5 | Pooled analysis of Cohen’s d-weighted effect size on serum triglycerides concentration with nutritional and behavioral interventions. The analysis was
stratified by placebo or active comparator. LFDT, Low fat diet; LCD, Low carbohydrate diet; CBT, Cognitive-behavioral therapy; Phys Act, Physical activity; Dark Choc,
Dark chocolate; AGE, Advanced glycation end-product; Hipocal, Hypocaloric diet; WEP, Water and Education Provision; LFM, Low fat milk; Micronut, Micronutrients;
PMR, Partial meal replacement; AntiBP, Antihypertensive medication; REML, Restricted maximum likelihood.

or non-random, predictable sequence. The attrition bias can
be considered if there was a poor description on how much
data was missing from each group, or the lack of reasons for
missing data and how they were considered in the analysis.
We were also interested in whether researchers used intention
to treat analysis, imputation of missing values, or just per
protocol analysis.
Both the scanning and selection of the studies, as well as the
data extraction with the Cochrane tool and the quality assessment
using the Jadad scale were procedures performed in a paired
manner by the investigators to avoid bias, and each step was

Frontiers in Medicine | www.frontiersin.org

discussed prior to the next using an online Delphi method due
to COVID-19 confinement.

Statistical Analysis
Sample size, means, and standard deviation were retrieved from
the data of the included studies. The summary of contrasts
between treatments was computed with Cohen’s-d differences.
All models were analyzed with Restricted maximum likelihood
(REML) random effects models, and the pooled effects were
described with 95% confidence intervals (95% CI). Heterogeneity
was assessed with I 2 statistics, and we use meta-regression to
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FIGURE 6 | Pooled analysis of Cohen’s d-weighted effect size on systolic blood pressure with nutritional and behavioral interventions. The analysis was stratified by
placebo or active comparator. LCD, Low carbohydrate diet; CBT, Cognitive-behavioral therapy; Phys Act, Physical activity; Dark Choc, Dark chocolate; AGE,
Advanced glycation end-product; Hipocal, Hypocaloric diet; WEP, Water and Education Provision; LFM, Low fat milk; Micronut, Micronutrients; AntiBP,
Antihypertensive medication; REML, Restricted maximum likelihood.

Studies Characteristics

analyze the heterogeneity. The Egger test was performed on
the slopes in the weighted regression of the effect size. These
statistical analyses were conducted with Stata 16.0 (StataCorp,
College Station TX).
The network meta-analysis was computed for studies with
medication only, because the designs of nutrition/behavior
studies did not allow us to construct networks. This analysis was
performed with Stata 16.0 and CINeMA to define the network
geometry, and effects comparisons. We did not have enough
samples of studies to perform a rankogram.

For the systematic review, we included 45 anti-obesity
national and multinational collaborative controlled clinical
trials involving overweight and obese Mexican adults
(>18 years) subjected to distinct weight-loss interventions:
pharmaceutical (25 studies), nutrition and behavioral (15
studies), surgical (2 studies), and alternative (3 studies)
interventions (Table 1). A total of 15 interventions were
composed exclusively by women, 5 by men, and 35 by
both sexes.

RESULTS

Participant Cities and States
With regard to participant cities, Mexico City had the
highest frequency of studies (38%, n = 17), followed
by Guadalajara (29%, n = 13). There were 11 out of
32 states in the included studies, three of which are
on the Mexico-U.S. border: Nuevo Leon, Tamaulipas,

We collected 634 studies from databases and after duplicate
removal identified 64 controlled clinical trials conducted in
Mexico from PubMed, 27 from Scopus, and 15 from Web
of Science.
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FIGURE 7 | Pooled analysis of Cohen’s d-weighted effect size on BMI reduction loss with drug (medication) treatment. The analysis was stratified by T2D status. The
Form1 and Form2 are described in the text, they are not approved by FDA. Met, Metformin; Sibut, Sibutramine; DHA, Docosahexaenoic acid; EPA, Eicosapentaenoic
acid; Orlit, Orlistat; Glim, Glimepiride; Phent, Phentermine; Top, Topiramate. REML, Restricted maximum likelihood.

and Baja
Table 1.

California.

The

details

are

described

for interventions that included participants with T2D (Fisher’s
exact test = 0.286).

in

Risk of Bias and Quality

Synthesis of Results

We performed a quality assessment at the intervention level.
The Jadad mean value for nutritional/behavioral interventions
was 3.6 (min 3, max 5), and for drug treatments was 3.7 (min
2, max 5). The nutrition/behavioral interventions had medium
risk of bias (by GRADE) in 95% (n = 18/19) and high risk of
bias in 5% (n = 1/19). Physical activity was difficult to blind.
The use of medication as intervention had very low risk of
bias in 32% (n = 7/22), medium 55% (n = 12/22) and high
risk in 14% (n = 3/22). No differences in bias were found

Frontiers in Medicine | www.frontiersin.org

This systematic review and meta-analysis included data from
2,074 participants in nutrition/behavioral interventions and
5,086 participants with medication. Excluding multicentric
international studies, there were 1,525 participants from
studies conducted exclusively in Mexico. The main
outcomes from individual studies are described in
Tables 2–4. Forest plots with the pooled analysis are in
Figures 3–10.
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FIGURE 8 | Pooled analysis of Cohen’s d-weighted effect size on waist circumference with drug (medication) treatment. The analysis was stratified by T2D status. The
Form1 and Form2 are described in the text, they are not approved by FDA. Met, Metformin; Sibut, Sibutramine; DHA, Docosahexaenoic acid; EPA, Eicosapentaenoic
acid; Orlit, Orlistat; Glim, Glimepiride; Phent, Phentermine; Top, Topiramate; REML, Restricted maximum likelihood.

Nutritional/Behavioral Interventions

and anthropometrical parameters (waist circumference)
the pooled analysis with Cohen-d supported additionally
loss of BMI and decrease in systolic blood pressure
(Figure 6).
Finally, the avoid of sugar-sweetened beverages (SSB) by water
substitution showed positive effect on plasma triglycerides, and
systolic blood pressure.

The comparisons between active nutrition/behavioral
interventions with placebo showed improvement for BMI
(Cohen-d, 95% CI, Figure 3) 0.2 (0.01, 0.38), waist circumference
0.27 (0.01, 0.53, Figure 4), triglycerides 0.34 (−0.02, 0.71;
Figure 5), and systolic blood pressure 0.21 (−0.07, 0.49,
Figure 6). The lowest heterogeneity was for BMI (I 2 = 41%) and
the highest for triglycerides (I 2 = 88%). Only one intervention
with physical activity showed an effect on BMI (Cohen-d of 0.3),
increase on HDL-c (Cohen-d 0.16), but with wide confidence
intervals. Most of these studies excluded T2D individuals,
therefore the glucose levels did not show difference between
compared groups.
Combining cognitive-behavioral therapy (CBT; goal setting,
problem-solving, and stimulus control) to either a lowfat diet (21% fat, ≤10% saturated fat, 25% protein, 54%
carbohydrates), or a low-carbohydrate diet (27% protein,
28% fat, 45% carbohydrate) produced significantly greater
short-term weight loss compared to diet alone. The use of
antioxidants with flavonoids contained in dark chocolate
showed favorable changes in biochemical parameters (total
cholesterol, triglycerides, and LDL-cholesterol level in blood)

Frontiers in Medicine | www.frontiersin.org

Drug Treatments and T2D Status
According to effect size, pharmacological treatments from studies
that included participants with T2D showed improvements
in BMI (Figure 7), waist circumference (Figure 8), and
glucose (Figure 9) in non-T2D individuals compared with
patients with T2D. BMI reduction in the T2D group had
a Cohen-d of 0.24 (0.13, 0.66) compared with non-T2D
reduction of 0.53 (0.27, 0.80); the waist circumference
had a Cohen-d of 0.22 (0.72, 1.16) compared with nonT2D 0.55 (0.03, 1.07); diastolic blood pressure 0.18 (0.3,
1.42) vs. 0.87 (0.33, 2.06), respectively. As expected, the
treatment had a large effect on glucose lowering in individuals
with T2D compared to non-T2D participants (Cohen-d
0.7 vs. 0.26, respectively).
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FIGURE 9 | Pooled analysis of Cohen’s d-weighted effect size on serum glucose serum concentration with drug (medication) treatment. The analysis was stratified by
T2D status. Met, Metformin; Orlit, Orlistat; Glim, Glimepiride; Phent, Phentermine; Top, Topiramate, REML, Restricted maximum likelihood.

Some medications used in Mexico had a large effect on weight
reduction (Figures 7, 8) in participants without T2D (Cohend about 0.9). For instance, the use of DHA (docosahexanoic
acid) 470 or 940 mg combined with EPA (eicosapentanoic acid)
580 or 1,160 mg, compared with placebo, and the use of two
different formulations (Formula 1: d-norpseudoephedrine 50 mg,
triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin
16.2 mg; and formula 2: d-norpseudoephedrine 50 mg, atropine
0.36 mg, aloin 16.2 mg.) for 6 months compared with placebo.
These medications are not approved for treatment of obesity by
FDA, and the formulations are not legally available for purchase
in the US, however, reports in US found thyroid intoxication
(65). The effect of liraglutide was between 0.3 and 0.6 including
participants from international samples. Participants with T2D
showed the use of phentermine 15 mg and topiramate 100 mg had
higher effect compared with phentermine 7.5 mg and placebo.
There was no replication for any of these studies, the Egger test
on a random model showed no small study effects on BMI for
18 interventions on nutrition/behavioral (p = 0.43), nor for 19
interventions on medication (p = 0.22).

Frontiers in Medicine | www.frontiersin.org

It is interesting that systolic blood pressure was modified
by non-pharmacological treatments, meanwhile, diastolic blood
pressure was modified in non-T2D participants treated with
medications (Figure 10). From the five analyzed studies with
medications, three of them included patients with hypertension
(prevalence of hypertension between 24 and 42%). The blood
pressure decreases with weight loss, the Trial of Hypertension
Prevention had a weight loss intervention arm, resulting in
reduction of both, systolic and diastolic, measurements (66).

Source of the Studies Heterogeneity
We made multiple Meta-Analyses clustering the studies into
stratum by type of intervention, T2D status, and group of
comparison. Additionally, we did meta regression analyzing
the mean age, BMI, months of treatment, comparison with
placebo and geographical location measured by latitude. Those
confounders that reached statistical significance for HDL-c
serum levels were the duration of the intervention [b = 1.07
(se 0.49) p = 0.03, b: beta value, se: standard error] and
the comparison vs. placebo [b = 4.4 (se 2.1) p = 0.04]. The
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FIGURE 10 | Pooled analysis of Cohen’s d-weighted effect size onof effect by Cohen-d in diastolic blood pressure with drug (medication) treatment. The analysis was
stratified by T2D status. The Form1 and Form2 are described in the text, they are not approved by FDA but approved by its Mexican counterpart, COFEPRIS. Met,
Metformin; Sibut, Sibutramine; Orlit, Orlistat; Glim, Glimepiride; Phent, Phentermine; Top, Topiramate; REML, Restricted maximum likelihood.

nutritional/behavioral interventions due to the design and the
small number of studies. Supplementary Figure 3 illustrates two
networks for studies with T2D patients, examining the efficacy
of pharmacological interventions on the studied variables,
one network for each comparison between treatments and
placebo (Supplementary Figure 3A) and with metformin
(Supplementary Figure 3B). These network diagrams provide
a graphical representation of how each intervention connects
to any other direct comparisons. Table 5 (matrix A and B) and
Supplementary Tables 1, 2 detail the complete matrix of results,
in which the comparative effects between drugs are shown in
terms of differences in standardized means.
The contrast matrix between pharmacological treatments with
placebo showed a decrease on BMI in every pharmacological
intervention, for instance, DHA 470 + EPA 580 mg was 0.816
(CI: 0.049, 1.582); DHA 940 + EPA 1,160 mg: 0.888 (CI: 0.117,
1.658); Formulation 1: 0.959 (CI: 0.324, 1.593); Formulation 2:
0.944 (CI: 0.301, 1.588); Liraglutide: 0.451 (CI: 0.141, 0.761).
On the other hand, the status of T2D consistently supported
metformin alone or in combinations was the most effective

triglyceride serum levels showed effects from the mean age of
the study [b = 1.3 (se 0.59) p = 0.03] and the geographic
location [b = −2.7 (se 1.3) p = 0.04]. However, the geographic
location was closely related with the type of intervention, for
example, studies located close to the Mexico-U.S. border used
physical activity interventions; meanwhile the South regions
used nutritional supplements. The diastolic blood pressure was
modified by the BMI [b = −0.49 (se 0.27) p = 0.067] and
geographical location [b = −0.9 (se 0.44) p = 0.04], however
these variables were influenced by the treatment with liraglutide
(Supplementary Figures 1, 2).

Network Meta-Analysis
A network meta-analysis of drug treatments and T2D status
was performed for BMI, diastolic blood pressure (DBP),
and glucose. The network meta-analysis included direct
comparisons constructed with connections between treatments,
and indirect comparisons using all possible connections between
treatments. All networks had the principles of coherence,
transitivity, and consistency. This analysis was not feasible for
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Matrix A represent the estimates of the effect of treatments (standardized mean differences and 95%CI) relative to placebo. The dosage of DHA and EPA are in mg per day. Form1, D-norpseudoephedrine 50 mg, triiodothyronine 75
ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg; Form2, D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg. These two formulations are not approved by FDA. Plc, Placebo. Matrix B shows estimates of the effect of
treatments (standardized mean differences) relative to metformin in patients with diabetes. Diac, Diacerin; Gim, Glimepiride; Met, Metformin.

0.898 (0.366, 1.431)

Met
−0.124 (−1.257, 1.009)

−0.267 (−0.749, 0.214)

−0.898 (−1.431, −0.366)

0.267 (−0.214, 0.749)

−0.204 (−0.675, 0.266)

Insulin
0.694 (−0.017, 1.404)

−0.631 (−1.349, 0.087)
Glim+Met

0.631 (−0.087, 1.349)

0.063 (−0.403, 0.529)

0.774 (−0.478, 2.026)

0.143 (−1.088, 1.374)

0.124 (−1.009, 1.257)

0.204 (−0.266, 0.675)
Glim

−0.694 (−1.404, 0.017)

−0.143 (−1.374, 1.088)

−0.063 (−0.529, 0.403)

−0.080 (−1.307, 1.147)

−0.774 (−2.026, 0.478)
BMI (Reference: metformin)

Matrix B: drugs (diabetic participants)

Diac+Met

Plc
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0.080 (−1.147, 1.307)

−0.451 (−0.761, −0.141)
Liraglutide

0.451 (0.141, 0.761)
0.959 (0.324, 1.593)

0.944 (0.301, 1.588)

0.508 (−0.198, 1.214)

0.888 (0.117, 1.658)
0.816 (0.049, 1.582)

0.365 (−0.462, 1.192)

0.436 (−0.394, 1.267)

0.493 (−0.221, 1.208)

−0.959 (−1.593, −0.324)

−0.944 (−1.588, −0.301)

−0.508 (−1.214, 0.198)

−0.493 (−1.208, 0.221)
Form2

Form1

0.014 (−0.541, 0.570)

−0.071 (−1.070, 0.927)
−0.143 (−1.138, 0.852)

−0.129 (−1.130, 0.872)

−0.057 (−1.061, 0.947)

−0.014 (−0.570, 0.541)

−0.816 (−1.582, −0.049)

−0.888 (−1.658, −0.117)

−0.365 (−1.192, 0.462)
0.129 (−0.872, 1.130)

0.057 (−0.947, 1.061)

0.143 (−0.852, 1.138)

0.071 (−0.927, 1.070)

0.072 (−0.672, 0.815)

DHA 940 + EPA 1160

DHA 470 + EPA 580

−0.072 (−0.815, 0.672)

BMI (Reference: placebo)

Matrix A: drugs (non-diabetic participants)

TABLE 5 | Network meta-analysis results matrix.
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−0.436 (−1.267, 0.394)
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intervention for reducing BMI compared to insulin: −0.898
(CI: −1.431, −0.366). Regarding glucose, the intervention
with insulin was more effective in reducing serum glucose
levels compared to metformin: −1.506 (CI: −2.084, −0.928);
Glimepiride + metformin: −1.332 (CI: −2.083, −0.581) and
Glimepiride: −1.332 (CI: −2.077, −0.587). In summary, the
interventions with the greatest contribution to the reduction of
DBP were metformin: −0.507 (CI: −0.994, −0.020) compared
to Glimepiride + metformin, and Glimepiride: −0.507 (−0.980,
−0.033) compared to Glimepiride + metformin. Monotherapy
interventions had greater efficacy on DBP compared to
dual therapies.

DISCUSSION
This systematic review and multiple meta-analyses by strata
summarize the existing evidence of weight loss as primary or
secondary aims in the adult population. Besides, we analyzed the
cardiometabolic risk traits affected by the proposed strategies
and clustered by the type of intervention, control group
and T2D status. Our analysis was limited to randomized
clinical studies conducted in Mexico or from international
multicentric studies with Mexican participants involving
nutrition, behavior, medication, or alternative medicine
interventions. Some interventions of interest were compared
with another active strategy (medication, behavior, physical
activity or any other than placebo). This strategy can blunt
the effect size of the intervention, because of the effect of
active comparators in metabolic and anthropometric variables.
We found that all studied interventions were better than
placebo, or better than the selected comparator, and many
of the published papers made individual paired contrasts
between final and basal values. However, we decided to
contrast treatments and reported the size of effects by
cardiometabolic risk traits. With this strategy we had the
advantage of computing the effect size over a maneuver the
researchers considered the best comparator. The results should
be interpreted considering these control groups defined by
the researchers.

Interventions and Cardiometabolic Risk
Traits
The 55 analyzed interventions (from 45 studies) were categorized
as nutritional/behavioral with a total sample of 1,407 participants.
Pharmacological interventions in Mexico included 1,134;
and multinational interventions added 1,307 participants
(Hispanics). Surgical procedures were 72, while alternative
treatments included 235 individuals. We obtained a total of 4,155
participants from these trials.
The nutritional/behavioral strategies included supplemental,
flavonoids, manipulation of macronutrient content diets (low
fat, low carb, high protein) with caloric restriction, water
consumption and physical activities. CBT combined with a
low-calorie diet showed beneficial effects on BMI and waist
circumference while combined with a low-fat diet decreased
glucose and triglycerides. A cardioprotective structured
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up weight changes for 24 months (61), in a second analysis, no
differences were found between these procedures after 5 years of
follow-up (75).

hypocaloric diet is more effective than the CBT approach
in reducing metabolic syndrome (54). Daily flavonoid-rich
chocolate (70% cocoa) intake improves fasting plasma glucose
levels and insulin resistance parameter (HOMA-IR) and
the lipid and glucose metabolism (41). The physical activity
showed benefic but small and non-significant effects for
the analyzed variables, due to the lack of enough sample
size. Other systematic reviews focused on physical activity
showed Hispanics had less leisure-time compared with other
groups in the U.S., the most common activity was walking,
but the most significant results were those with moderate to
vigorous physical activity (67). It will be crucial to increase
legislative policies to build environments that increase available
opportunities for physical activities, particularly for this
fast-growing population group.
Adherence to diet and exercise programs (45–60 min/d, 5 days
per week) are part of the nutritional/behavioral interventions.
Other studies reporting that water consumption habit (2–3
L/day) and partially decreasing sugar-sweetened beverage (SSB)
intake of at least 250 kcal/d, with nutritional counseling was
effective in increasing water intake (63), and additionally reduces
cardiometabolic risks of drinking or eating less sugar in the diet
promoting health benefits, although we found positive effect on
plasma triglycerides and systolic blood pressure in our analysis,
perhaps a consequence of the reduction of the SSB consumption.
The drug treatment in groups of participants with T2D,
showed small effect size on improvement on BMI, waist
circumference and triglycerides compared with larger effects for
non-T2D. The orlistat group in T2D showed weight loss (BMI
and waist circumference) lower level of glucose, triglycerides,
and systolic blood pressure. Comparing these findings with other
studies made in Mexican Americans living in the border shows
the difficulty of losing weight with programs on self-management
education, but the HbA1c improved (68).
Medication showed larger size of effects on BMI for combined
formulations like orlistat, phentermine with topiramate, both
approved by regulatory agencies. Other formulations like
the combination of triiodothyronine with phentermine (nonapproved by FDA but approved by its Mexican counterpart,
COFEPRIS—Federal Committee for Protection from Sanitary
Risks), and combination of DHA and EPA showed effect on
BMI. The authors of the formulations did not show the result
on serum glucose neither reported any adverse effect. There was
no replication for any of these treatments. We found a couple
of sibutramine trials. This is a retired medication because the
cardiovascular risk was greater than the benefits (69), especially
for the difficulty to identify patients with silent cardiovascular
disease (70).
Surgical intervention is the most effective treatment for
patients with morbid obesity (71). The percentage of body weight
loss with this intervention ranges between 33 and 77% in a
period of 24 months, thus demonstrating its effectiveness (72, 73).
However, in our surgical papers, no significant differences were
found in the percentage of weight loss, this due to the fact
that both the intervention group and the control group had
equivalent surgeries (74). One of the studies compared banded
vs. unbanded laparoscopic roux-en-Y gastric bypass and follow

Frontiers in Medicine | www.frontiersin.org

Risk of Bias
In general, many of the studied interventions are challenging
to blind for obvious reasons. For example, a comparison
of nutritional interventions vs. exercise or CBT cannot be
blind. However, there is a possibility to blind the evaluators,
but no studies explicitly describe this strategy. We found
that heterogeneity of the results was partially attributable to
basal differences between contrasting groups, for example in
the study of Rosado et al. (46) the diastolic and systolic
blood pressure were significantly different between the studied
low fat milk groups compared with controls. Some surgical
studies for weight loss made in the Instituto de Nutrición
Salvador Zubirán in Mexico City blinded the abdominal wall
for patients and evaluators when they compared the open
abdominal approach vs. the laparoscopic method. The risk of
bias can be lessened but still can compromise the results of the
studies. The difficulty in addressing nutritional or behavioral
interventions is manifest in studies analyzing racial/ethnic
disparities. Multilevel church-based interventions considering
socio-ecological influence showed a greater impact if they
consider program interventions tailored to specific communities.

Limitations
The most important limitations are the lack of replication studies
with the same medications, and the small sample size in most of
the studies. There was a wide variety for the selection criteria of
participants (i.e., some studies had too specific eligibility criteria
for sex, age and BMI compared with other studies with wide
range of options), and, despite similar genetic background, the
participants live in sites embedded in cultural diversity (i.e.,
Mexico City’s environment problems differ from those in States
close to the Mexico-U.S. border). We address a broad question
regarding the cardiometabolic traits and found a considerable
heterogeneity of the studies. We addressed this problem using
meta-regression to statistically weight the main confounders
across studies and the use of a network Meta-Analysis to compute
the magnitude of contrasts between treatment effects. Due to
these limitations the obtention of unstable coefficients is possible,
therefore, these analyses should be repeated in the future with a
greater number of studies.
The small sample sizes from many of the included studies
resulted in low statistical power for contrasting between
treatment, and the lack of replication studies increased the
standard error for the analysis. The new medications approved by
FDA have been tested scarcely in the Mexican population. About
44% of the studies were performed in the limit time of placebo
effects (about 12 weeks), but those with more time showed effects
on the HDL cholesterol levels.
Southern states of Mexico are experiencing an epidemiological
transition toward mortality causes, like T2D, toward the
Northern states (76). The Studies we gathered do not have
information regarding the socioeconomic strata of the patients,
we do not have data to analyze if social determinants affect the
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Clinical experience of researchers on obesity began in 1959
in Mexico City, yet publications on obesity interventions in
randomized clinical trials studies in Mexico did not appear
until 1996, mainly focused on pharmaceutical, nutritional, or
physical activity interventions. Adult participants included in
these studies were predominantly from the central and northern
Mexican states, with a clear absence from the costal and southern
states. Anti-obesity studies in the Mexican population include
small samples and reduced time for interventions. A strategy
to improve the statistical power for the studies is to conduct
multicentric studies, and a compromise from the State or private
industries to provide sufficient financial resources.
A national research network is feasible for answering relevant
questions regarding anti-obesity interventions and its metabolic
consequences. It is clear that not all cardiometabolic traits have
the same response to the intervention. The inclusion of Mexican
Americans and Mexican immigrants living in the U.S., would
be desirable to clarify the importance of different approaches to
tackle this problem.

Supplementary Figure 1 | Meta- regression of nutritional/behavioral effects on
the mean difference in HDL-C (A) and triglycerides (B) concentrations, adjusted
by mean age, BMI, duration of treatment (months), geographical latitude, and use
of placebo or active comparator. The gray zone represents the 95% CI of the
regression. Liraglutide was used in participants with the highest obesity and in
geographic locations in northern Mexico. AGE’s, Advanced glycation end-product;
AntiBP, Antiblood pressure medication; CBT, Cognitive-behavioral therapy; Dark
Choc, Dark chocolate, Hipol; LCD, Low carbohydrate diet; LFDt, Low fat diet;
LFM, Low fat milk, Micronut; Phys Act, Physical activity; PMR, Partial meal
replacement; WEP, Water and education provision.
Supplementary Figure 2 | Meta regression of medication effects on the mean
difference in diastolic blood pressure adjusted by mean age, BMI, duration of
treatment (months), geographical latitude, and use of placebo or active
comparator. The (A) shows the effect of BMI and the (B) the geographical
location. The gray zone represents the 95%CI of the regression. Liraglutide was
used in participants with the highest obesity and in geographical locations in
northern Mexico. The Form1 and Form2 are described in the text, they are not
approved by FDA. Met, Metformin; Sibut, Sibutramine; Orlit, Orlistat; Glim,
Glimepiride; Phent, Phentermine; Top, Topiramate.
Supplementary Figure 3 | Network meta-analysis of studies examining the
efficacy of drug treatments in patients with obesity on (A) BMI in non-diabetic
patients compared to placebo, (B) BMI in patients with diabetes compared to
metformin. The colors of the edges and nodes refer to the risk of bias: low (green),
moderate (yellow), and high (red). DHA and EPA doses are in mg per day. Met,
Metformin; Diac+Met, Diacerin + Metformin. The Form1 and Form2 are described
in the text, they are not approved by FDA but approved by its Mexican
counterpart, COFEPRIS. Plc, Placebo.
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Supplementary Table 1 | Network meta-analysis results matrix. Estimates of the
effect of treatments (standardized mean differences with 95% CI) relative to
placebo (Plc). The Form1 and Form2 are described in the text, they are not
approved by FDA.

Supplementary Table 2 | Network meta-analysis results matrix. Estimates of the
effect of treatments (standardized mean differences with 95% CI) relative to
metformin in patients with diabetes. The Form1 and Form2 are described in the
text, they are not approved by FDA.
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